O. S. Saburova
Research Subjects
O. S. Saburova has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Ivan Melnikov
National Medical Research Centre of Cardiology Named After Academician E.I. Chazov, Ministry of Health of the Russian Federation, 15A Akademika Chazova Street, 121552 Moscow, Russia
4 shared publications - Zufar A. Gabbasov
National Medical Research Centre of Cardiology Named After Academician E.I. Chazov, Ministry of Health of the Russian Federation, 15A Akademika Chazova Street, 121552 Moscow, Russia
4 shared publications - Sergey G. Kozlov
National Medical Research Centre of Cardiology Named After Academician E.I. Chazov, Ministry of Health of the Russian Federation, 15A Akademika Chazova Street, 121552 Moscow, Russia
3 shared publications - A. I. Gindler
Lipetsk City Emergency Hospital No 1
1 shared publication - Andrey Pavlovich Momot
Altai Branch of the National Medical Research Center of Hematology, Russian Federation, Russia
1 shared publication - Konstantin G. Guria
National Medical Research Centre of Cardiology Named After Academician E.I. Chazov, Ministry of Health of the Russian Federation, 15A Akademika Chazova Street, 121552 Moscow, Russia
1 shared publication
Latest Publications
- 23 October 2026
- Published by Media Sphere Publishing Group in Russian Cardiology Bulletin
- Vol. 21 (3)
In-hospital and post-hospital serum high-sensitivity and monomeric C-reactive protein in patients with acute ST segment elevation myocardial infarction and previous COVID-19
Objective. To analyze in-hospital and post-hospital (up to 6 months) serum hsCRP and mCRP in patients with acute ST-segment elevation myocardial infarction (STEMI) and previous COVID-19. Material and methods. There were 140 patients with STEMI stratified into 2 groups: 1 — 52 STEMI patients with COVID-19 1.5—6 months before acute coronary syndrome (ACS), 2 — 88 patients with STEMI and no previous COVID-19. PCI with stenting of infarct-related artery was performed on the first day. Serum hsCRP and mCRP were determined in 2 and 10 days, 1 and 6 months after MI. Results. Serum mCRP was higher in the main group at all time points: by 5.09 times after 2 day, 13.50 times after 10 days, 5.70 times after 1 month and 2.41 times after 6 months. In-hospital serum hsCRP was higher in the main group (by 2.05 times after 2 days and 3.36 times after 10 days). Serum hsCRP after 1 and 6 months was equivalent in both groups. Dynamics of serum mCRP and hsCRP was multidirectional after 10 days (mCRP increased, hsCRP did not change in the main group, and both parameters decreased in the control group). After 1 and 6 months, dynamics of these parameters was unidirectional and positive in both groups. Conclusion. Patients with STEMI and previous COVID-19 are characterized by higher concentration of mCRP in the first 6 months and hsCRP in the first month of treatment. This indicates more severe inflammatory reaction in the first 6 months after STEMI.
- 23 October 2026
- Published by Media Sphere Publishing Group in Russian Cardiology Bulletin
- Vol. 21 (3)
In-hospital and post-hospital serum high-sensitivity and monomeric C-reactive protein in patients with acute ST segment elevation myocardial infarction and previous COVID-19
Objective. To analyze in-hospital and post-hospital (up to 6 months) serum hsCRP and mCRP in patients with acute ST-segment elevation myocardial infarction (STEMI) and previous COVID-19. Material and methods. There were 140 patients with STEMI stratified into 2 groups: 1 — 52 STEMI patients with COVID-19 1.5—6 months before acute coronary syndrome (ACS), 2 — 88 patients with STEMI and no previous COVID-19. PCI with stenting of infarct-related artery was performed on the first day. Serum hsCRP and mCRP were determined in 2 and 10 days, 1 and 6 months after MI. Results. Serum mCRP was higher in the main group at all time points: by 5.09 times after 2 day, 13.50 times after 10 days, 5.70 times after 1 month and 2.41 times after 6 months. In-hospital serum hsCRP was higher in the main group (by 2.05 times after 2 days and 3.36 times after 10 days). Serum hsCRP after 1 and 6 months was equivalent in both groups. Dynamics of serum mCRP and hsCRP was multidirectional after 10 days (mCRP increased, hsCRP did not change in the main group, and both parameters decreased in the control group). After 1 and 6 months, dynamics of these parameters was unidirectional and positive in both groups. Conclusion. Patients with STEMI and previous COVID-19 are characterized by higher concentration of mCRP in the first 6 months and hsCRP in the first month of treatment. This indicates more severe inflammatory reaction in the first 6 months after STEMI.
- 22 April 2024
- Published by Media Sphere Publishing Group in Russian Cardiology Bulletin
- Vol. 19 (4)
Fibrin monomer in diagnosis of cardiovascular diseases
This review discusses current issues of fibrin monomer as a marker for diagnosing cardiovascular diseases. The authors analyzed available literature data on the feasibility of fibrin monomer for assessing the risks of thrombotic complications, their severity and pre-thrombotic conditions. In the context of various cardiovascular diseases, fibrin monomer concentration allows identifying early stages of DIC syndrome and assessing its severity, differentiating the type of strokes (embolic or not), assessing the risks of postoperative deep vein thrombosis and thromboembolic complications. The shortcomings of current methods for analysis of fibrin monomer (insufficient standardization and no universal threshold values) are also considered. The authors analyze the prospects for further development of more advanced methods for analysis of fibrin monomer concentrations and their subsequent introduction into clinical practice.
- 22 April 2024
- Published by Media Sphere Publishing Group in Russian Cardiology Bulletin
- Vol. 19 (4)
Fibrin monomer in diagnosis of cardiovascular diseases
This review discusses current issues of fibrin monomer as a marker for diagnosing cardiovascular diseases. The authors analyzed available literature data on the feasibility of fibrin monomer for assessing the risks of thrombotic complications, their severity and pre-thrombotic conditions. In the context of various cardiovascular diseases, fibrin monomer concentration allows identifying early stages of DIC syndrome and assessing its severity, differentiating the type of strokes (embolic or not), assessing the risks of postoperative deep vein thrombosis and thromboembolic complications. The shortcomings of current methods for analysis of fibrin monomer (insufficient standardization and no universal threshold values) are also considered. The authors analyze the prospects for further development of more advanced methods for analysis of fibrin monomer concentrations and their subsequent introduction into clinical practice.
- Open Access
- 24 June 2020
- Published by NII KPSSZ in Complex Issues of Cardiovascular Diseases
- Vol. 9 (2) , 45-52
Monomeric C-reactive protein in coronary artery disease
Современные возможности определения и применения в клинике мономера С-реактивного белка
- 24 June 2020
- Published by NII KPSSZ in Complex Issues of Cardiovascular Diseases
- Vol. 9 (2) , 45-52
Open AccessMonomeric C-reactive protein in coronary artery disease
Современные возможности определения и применения в клинике мономера С-реактивного белка
- Open Access
- 14 June 2019
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- No. 5,p. 56-61
Monomeric C-reactive protein and local inflammatory reaction in the wall of the coronary arteries in patients with stable coronary artery disease
Мономерный C-реактивный белок и локальная воспалительная реакция в стенке коронарных артерий у больных стабильной ишемической болезнью сердца
- 14 June 2019
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- No. 5,p. 56-61
Open AccessMonomeric C-reactive protein and local inflammatory reaction in the wall of the coronary arteries in patients with stable coronary artery disease
Мономерный C-реактивный белок и локальная воспалительная реакция в стенке коронарных артерий у больных стабильной ишемической болезнью сердца